Floxuridine vs Hydroxyurea — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Antimetabolite

Floxuridine

First FDA approval: 2001-03-15

Antimetabolite

Hydroxyurea

Brand: DROXIA

First FDA approval: 1998-10-19

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$0.199Per unit

Average NADACAcross all dosage forms and strengths

—

$5.91Up to $62.03

Generic manufacturersActive ANDA holders — FDA Orange Book

22 total ANDAs filed

44 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$21.1MFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

805K216K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$26Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

—Zero PA friction

38Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

—None

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes2 manufacturers

Yes4 manufacturers